Find a Review

Target dates in the pCODR review process are estimated based upon timelines outlined in the pCODR Procedures and notification provided by the manufacturer. Changes to these dates may occur during the process and these changes will be explained in the Find a Review Details as needed.

Brand Name / Generic Name

Tumour Type / Indication

Review Status

Last Updated

Votrient
Pazopanib

Genitourinary
Metastatic renal cell carcinoma

Notification to Implement Issued

January 20, 2012

Yervoy
Ipilimumab

Melanoma
Advanced Melanoma

Notification to Implement Issued

Sutent
Sunitinib malate

Gastrointestinal
Pancreatic neuroendocrine tumours

Notification to Implement Issued

Zelboraf
Vemurafenib

Melanoma
Advanced Melanoma

Halaven
Eribulin Mesylate

Breast
Metastatic Breast Cancer

Afinitor
Everolimus

Gastrointestinal
Pancreatic neuroendocrine tumours

Xalkori
Crizotinib

Lung
Advanced Non-Small Cell Lung Cancer

Treanda
bendamustine hydrochloride

Lymphoma & Myeloma
Non-Hodgkin lymphoma (NHL)

Treanda
bendamustine hydrochloride

Leukemia
chronic lymphocytic leukemia (CLL)

Votrient
Pazopanib Hydrochloride

Sarcoma
soft tissue sarcoma (STS)

Last updated: May 18, 2012